SG11201903331QA - Restimulation of cryopreserved tumor infiltrating lymphocytes - Google Patents
Restimulation of cryopreserved tumor infiltrating lymphocytesInfo
- Publication number
- SG11201903331QA SG11201903331QA SG11201903331QA SG11201903331QA SG11201903331QA SG 11201903331Q A SG11201903331Q A SG 11201903331QA SG 11201903331Q A SG11201903331Q A SG 11201903331QA SG 11201903331Q A SG11201903331Q A SG 11201903331QA SG 11201903331Q A SG11201903331Q A SG 11201903331QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- october
- rule
- basal
- restimulation
- Prior art date
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title abstract 5
- 230000034659 glycolysis Effects 0.000 abstract 2
- 230000002414 glycolytic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940126587 biotherapeutics Drugs 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000010034 metabolic health Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dentistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1#11101111 01110101011111 01111101 0 011111111111 010 1110 11111 011111110 1111 0111111 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/081473 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, C12N 5/0783 (2010.01) A61K 35/17 (2015.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US2017/058610 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 26 October 2017 (26.10.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/413,387 26 October 2016 (26.10.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/413,283 26 October 2016 (26.10.2016) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/415,452 31 October 2016 (31.10.2016) US KM, ML, MR, NE, SN, TD, TG). (71) Applicant: IOVANCE BIOTHERAPEUTICS, INC. Declarations under Rule 4.17: [US/US]; 999 Skyway Road, Suite 150, San Carlos, CA - as to applicant's entitlement to apply for and be granted a 94070 (US). patent (Rule 4.1700) (72) Inventors: FRANK, Ian; 8302 Old Town Drive, Tampa, - as to the applicant's entitlement to claim the priority of the _ FL 33647 (US). LOTZE, Michael, T.; 5134 Westminster earlier application (Rule 4.17(iii)) Place, Pittsburgh, PA 15232 (US). Published: - (74) Agent: MACDOUGALL, Christina, A. et al.; Morgan, Lewis & Bockius LLP, One Market, Spear Tower, San Fran- - with international search report (Art. 21(3)) - before the expiration of the time limit for amending the _ = cisco, CA 94105 (US). claims and to be republished in the event of receipt of = Designated States (unless otherwise indicated, for every amendments (Rule 48.2(h)) = (81) kind of national protection available): AE, AG, AL, AM, _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, - HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = Title: RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES = (54) = Figure 1 = = = = Table 1. = Fresh Product Cryopreserved Product )8 147 3 Al 11111111111 Tumor Type post-Harvest post-Thaw post-restimulation Malignant Melanoma OxPhos (pmol/min) (M1053T) Basal respiration 17.5 ± 4.4 9.5 ± 4.9 22.5 ± 2.5 REP SRC 19.3 ± 9.0 27.5± 12.1 16.8 ± 2.6 SRC (% of basal) 210.6 ± 51.4 389.8 ± 127.4 174.7 ± 11.3 Glycolysis (mpH/min) Basal glycolysis 31.1 ± 4.4 22.5± 1.2 103.1 ± 5.4 Glycolytic Reserve 26.4± 5.5 20.7 ± 2.2 15.9 ± 7.7 Glycolytic Res (% of basal) 185.1 ± 17.6 192.0 ± 9.9 115.5 ± 7.4 .. .... 7 .... GC Il 0 el (57) : The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and in- creased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious 0 infusion after re- stimulation.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413387P | 2016-10-26 | 2016-10-26 | |
US201662413283P | 2016-10-26 | 2016-10-26 | |
US201662415452P | 2016-10-31 | 2016-10-31 | |
PCT/US2017/058610 WO2018081473A1 (en) | 2016-10-26 | 2017-10-26 | Restimulation of cryopreserved tumor infiltrating lymphocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903331QA true SG11201903331QA (en) | 2019-05-30 |
Family
ID=60327390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903331QA SG11201903331QA (en) | 2016-10-26 | 2017-10-26 | Restimulation of cryopreserved tumor infiltrating lymphocytes |
Country Status (18)
Country | Link |
---|---|
US (22) | US11026974B2 (en) |
EP (2) | EP4180520A1 (en) |
JP (2) | JP2019532652A (en) |
KR (1) | KR20190066073A (en) |
CN (1) | CN110099998A (en) |
AU (1) | AU2017347851B2 (en) |
BR (1) | BR112019008305A2 (en) |
CA (1) | CA3041678A1 (en) |
DK (1) | DK3532607T3 (en) |
FI (1) | FI3532607T3 (en) |
HR (1) | HRP20240436T1 (en) |
IL (1) | IL266209A (en) |
LT (1) | LT3532607T (en) |
MX (1) | MX2019004707A (en) |
PT (1) | PT3532607T (en) |
RS (1) | RS65448B1 (en) |
SG (1) | SG11201903331QA (en) |
WO (1) | WO2018081473A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
JP7093771B2 (en) | 2016-07-07 | 2022-06-30 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Programmed Death 1 Ligand 1 (PD-L1) -binding protein and its usage |
EP4180520A1 (en) * | 2016-10-26 | 2023-05-17 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
JP7125392B2 (en) | 2016-11-17 | 2022-08-24 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Remnant tumor-infiltrating lymphocytes and methods of preparing and using the same |
JP2020503351A (en) | 2017-01-06 | 2020-01-30 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Proliferation of tumor infiltrating lymphocytes by potassium channel agonist and its therapeutic use |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
JOP20190224A1 (en) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
MX2019014023A (en) | 2017-05-24 | 2020-02-17 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer. |
US11819517B2 (en) | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
MX2020004967A (en) * | 2017-11-17 | 2020-08-27 | Iovance Biotherapeutics Inc | Til expansion from fine needle aspirates and small biopsies. |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
BR112020018658A2 (en) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMU-NOTERAPY |
AU2019257749A1 (en) | 2018-04-27 | 2020-10-22 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
TW202031273A (en) * | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
EP3852524B1 (en) * | 2018-09-20 | 2023-06-28 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
AU2019360928B2 (en) | 2018-10-15 | 2023-11-09 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
CA3118616A1 (en) * | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
CN113272421A (en) | 2018-11-05 | 2021-08-17 | 艾欧凡斯生物治疗公司 | Method for generating tumor infiltrating lymphocytes and use thereof in immunotherapy |
CA3118634A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
US20220193131A1 (en) | 2018-12-19 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof |
AU2020233284A1 (en) * | 2019-03-01 | 2021-09-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
EP4069237A1 (en) | 2019-12-04 | 2022-10-12 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
WO2021118990A1 (en) * | 2019-12-11 | 2021-06-17 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
IL294388A (en) | 2020-01-14 | 2022-08-01 | Synthekine Inc | Il2 orthologs and methods of use |
CA3172902A1 (en) * | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
EP3892720A1 (en) | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
EP4142746A1 (en) | 2020-04-28 | 2023-03-08 | Achilles Therapeutics UK Limited | T cell therapy |
TW202208617A (en) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
EP4146793A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
CN115698267A (en) | 2020-05-29 | 2023-02-03 | 上海君赛生物科技有限公司 | Seed cell culture medium for tumor infiltrating lymphocytes and application thereof |
WO2022066894A1 (en) * | 2020-09-24 | 2022-03-31 | The Jackson Laboratory | Humanized mouse models for assessing immune cell therapy |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
JP2023546359A (en) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy |
TW202237822A (en) * | 2020-11-19 | 2022-10-01 | 大陸商蘇州沙礫生物科技有限公司 | Processes for culturing tumor infiltrating lymphocytes and use thereof |
EP4259164A1 (en) | 2020-12-11 | 2023-10-18 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
CA3202473A1 (en) | 2020-12-17 | 2022-06-23 | Friedrich Graf Finckenstein | Treatment of cancers with tumor infiltrating lymphocytes |
CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
CN114686430A (en) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | Method for preparing TIL |
TW202241508A (en) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
TW202305360A (en) | 2021-03-25 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
JP2024515189A (en) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy - Patents.com |
CA3219148A1 (en) | 2021-05-17 | 2022-11-24 | Frederick G. Vogt | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
KR20240023426A (en) | 2021-06-22 | 2024-02-21 | 아킬레스 테라퓨틱스 유케이 리미티드 | Method for producing antigen-specific T cells |
WO2022271847A1 (en) * | 2021-06-24 | 2022-12-29 | Instil Bio, Inc. | Processing of tumor infiltrating lymphocytes |
EP4373270A2 (en) | 2021-07-22 | 2024-05-29 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023023114A1 (en) * | 2021-08-17 | 2023-02-23 | Orgenesis Inc. | Tumor infiltrating lymphocytes with increased metabolic activity |
TW202328439A (en) | 2021-09-09 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | Processes for generating til products using pd-1 talen knockdown |
CA3235824A1 (en) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
WO2024112711A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Methods for assessing proliferation potency of gene-edited t cells |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
ES2382636T3 (en) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Method for producing compositions for improved administration of bioactive molecules |
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
ITMI20022118A1 (en) | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | PROCEDURE FOR THE LARGE SCALE CULTURE OF T-LYMPHOCYTES IN A HOMOGENEOUS SYSTEM. |
AU2004280623B2 (en) | 2003-10-08 | 2010-12-02 | Wilson Wolf Manufacturing, LLC | Cell culture methods and devices utilizing gas permeable materials |
ES2427646T5 (en) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies against programmed death 1 (PD1) and methods for the treatment of cancer through the use of anti-PD-1 antibodies alone or in combination with other immunotherapeutic agents |
MX2007015942A (en) | 2005-07-01 | 2008-03-07 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1). |
EP2203746B1 (en) | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
CN102762719A (en) | 2009-12-08 | 2012-10-31 | 威尔森沃尔夫制造公司 | Improved methods of cell culture for adoptive cell therapy |
WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
WO2013057500A1 (en) | 2011-10-21 | 2013-04-25 | Cell Medica Limited | Device for the aseptic expansion of cells |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
SG10202111564SA (en) | 2012-05-18 | 2021-12-30 | Wilson Wolf Mfg Corporation | Improved methods of cell culture for adoptive cell therapy |
IL288241B2 (en) | 2012-06-11 | 2023-10-01 | Wilson Wolf Mfg Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2014133568A1 (en) | 2013-03-01 | 2014-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
RU2671897C2 (en) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Methods of producing enriched populations of tumour-reactive t cells from tumour |
CN103396991A (en) * | 2013-05-02 | 2013-11-20 | 陈晚华 | Method for rapidly and efficiently amplifying tumor infiltrating lymphocytes |
CN110564612A (en) | 2013-06-24 | 2019-12-13 | 威尔逊沃夫制造公司 | closed system devices and methods for gas permeable cell culture processes |
JP6616295B2 (en) | 2013-07-15 | 2019-12-04 | アメリカ合衆国 | Method for preparing anti-human papillomavirus antigen T cells |
US10233425B2 (en) | 2013-09-16 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | CD137 enrichment for efficient tumor infiltrating lymphocyte selection |
JP2017511375A (en) | 2014-03-20 | 2017-04-20 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Tumor infiltrating lymphocytes for adoptive cell therapy |
WO2015157636A1 (en) * | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
KR102441940B1 (en) | 2014-06-11 | 2022-09-08 | 폴리바이오셉트 게엠베하 | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
EP4270006A3 (en) | 2014-06-13 | 2024-01-10 | Immudex ApS | General detection and isolation of specific cells by binding of labeled molecules |
AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
EP3034092A1 (en) * | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
FR3040396A1 (en) | 2015-06-30 | 2017-03-03 | Chu Nantes | PROCESS FOR CRYOPRESERVATION OF LYMPHOCYTES INFERATING THE TUMOR |
CN105602901B (en) * | 2016-03-11 | 2020-01-31 | 广州赛莱拉干细胞科技股份有限公司 | Bioreactor, stirring paddle thereof and method for culturing TIL cells by using bioreactor |
PL3512547T3 (en) | 2016-09-14 | 2021-03-08 | Abbvie Biotherapeutics Inc. | Anti-pd-1 antibodies |
EP4180520A1 (en) * | 2016-10-26 | 2023-05-17 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
JP7125392B2 (en) * | 2016-11-17 | 2022-08-24 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Remnant tumor-infiltrating lymphocytes and methods of preparing and using the same |
JP2020503351A (en) * | 2017-01-06 | 2020-01-30 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Proliferation of tumor infiltrating lymphocytes by potassium channel agonist and its therapeutic use |
KR20190104048A (en) | 2017-01-06 | 2019-09-05 | 이오반스 바이오테라퓨틱스, 인크. | Expansion of Tumor Infiltrating Lymphocytes (TIL) with Tumor Necrosis Factor Receptor Superfamily (TNFRSF) Agonists and Treatment Combinations of TILs and TNFRSF Agonists |
US11254913B1 (en) * | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
JOP20190224A1 (en) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
AU2018266202A1 (en) | 2017-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
US11819517B2 (en) * | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
US11713446B2 (en) * | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2021216920A1 (en) * | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
US11918517B2 (en) * | 2021-10-07 | 2024-03-05 | Stryker Corporation | Cover systems for blocking apertures of patient support apparatuses |
-
2017
- 2017-10-26 EP EP22203248.4A patent/EP4180520A1/en active Pending
- 2017-10-26 AU AU2017347851A patent/AU2017347851B2/en active Active
- 2017-10-26 PT PT177980455T patent/PT3532607T/en unknown
- 2017-10-26 KR KR1020197014832A patent/KR20190066073A/en not_active Application Discontinuation
- 2017-10-26 CA CA3041678A patent/CA3041678A1/en active Pending
- 2017-10-26 MX MX2019004707A patent/MX2019004707A/en unknown
- 2017-10-26 FI FIEP17798045.5T patent/FI3532607T3/en active
- 2017-10-26 JP JP2019521434A patent/JP2019532652A/en active Pending
- 2017-10-26 DK DK17798045.5T patent/DK3532607T3/en active
- 2017-10-26 EP EP17798045.5A patent/EP3532607B1/en active Active
- 2017-10-26 BR BR112019008305A patent/BR112019008305A2/en unknown
- 2017-10-26 US US15/751,440 patent/US11026974B2/en active Active
- 2017-10-26 HR HRP20240436TT patent/HRP20240436T1/en unknown
- 2017-10-26 SG SG11201903331QA patent/SG11201903331QA/en unknown
- 2017-10-26 RS RS20240474A patent/RS65448B1/en unknown
- 2017-10-26 LT LTEPPCT/US2017/058610T patent/LT3532607T/en unknown
- 2017-10-26 CN CN201780080304.5A patent/CN110099998A/en active Pending
- 2017-10-26 WO PCT/US2017/058610 patent/WO2018081473A1/en unknown
-
2018
- 2018-02-08 US US15/892,331 patent/US10517894B2/en active Active
-
2019
- 2019-04-23 IL IL266209A patent/IL266209A/en unknown
-
2021
- 2021-04-08 US US17/225,993 patent/US11058728B1/en active Active
- 2021-04-16 US US17/233,295 patent/US11123371B2/en active Active
- 2021-04-16 US US17/233,299 patent/US11141438B2/en active Active
- 2021-04-16 US US17/233,290 patent/US11179419B2/en active Active
- 2021-08-27 US US17/459,988 patent/US11304980B2/en active Active
- 2021-09-21 US US17/480,900 patent/US11311578B2/en active Active
- 2021-09-21 US US17/480,935 patent/US11344580B2/en active Active
- 2021-09-21 US US17/480,919 patent/US11351198B2/en active Active
- 2021-09-21 US US17/480,941 patent/US11266694B2/en active Active
- 2021-09-21 US US17/480,916 patent/US11351197B2/en active Active
- 2021-12-09 US US17/547,192 patent/US11351199B2/en active Active
- 2021-12-09 US US17/547,190 patent/US11344581B2/en active Active
- 2021-12-11 US US17/548,502 patent/US11364266B2/en active Active
- 2021-12-11 US US17/548,504 patent/US11369637B2/en active Active
-
2022
- 2022-05-31 US US17/829,087 patent/US20220378837A1/en active Pending
- 2022-08-11 US US17/819,209 patent/US11857573B2/en active Active
- 2022-08-11 US US17/819,214 patent/US11969444B2/en active Active
- 2022-08-11 US US17/819,219 patent/US11975028B2/en active Active
- 2022-08-15 US US17/819,910 patent/US11865140B2/en active Active
- 2022-08-15 US US17/819,909 patent/US20230030883A1/en active Pending
-
2023
- 2023-06-22 JP JP2023102781A patent/JP2023126265A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903331QA (en) | Restimulation of cryopreserved tumor infiltrating lymphocytes | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908994RA (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
SG11201808913WA (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201810522UA (en) | Anti-cd40 antibodies and their uses | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201807250PA (en) | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression |